Delving into the Latest Updates on Esomeprazole Strontium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Esomeprazole strontium (USAN), Esomeprazole strontium tetrahydrate

+ [1]

Target

Proton pump

Action

inhibitors

Mechanism

Proton pump inhibitors

Therapeutic Areas

Digestive System Disorders

Active Indication

Duodenal Ulcer

Inactive Indication

Gastroesophageal RefluxHelicobacter pylori infectionStomach Ulcer+ [1]

Originator Organization

Hanmi Pharmaceutical Co., Ltd.

Active Organization

Hanmi Pharmaceutical Co., Ltd.

Inactive Organization

Belcher Pharmatech LLC

Drug Highest PhaseApproved

First Approval Date

United States (06 Aug 2013),

Duodenal UlcerGastroesophageal RefluxHelicobacter pylori infection+ [2]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC17H19N3O3S

InChIKeySUBDBMMJDZJVOS-DEOSSOPVSA-N

CAS Registry119141-88-7

View All Structures (2)

This is a randomized, open-label, two-cycle clinical study to evaluate the drug interaction, food effect and pharmacokinetics of IBI351 and esomeprazole in healthy subjects. A total of two cohorts were planned to be enrolled in each cohort. Cohort 1: This cohort investigated the effect of esomeprazole on the pharmacokinetics of IBI351 in healthy subjects. Cohort 2: This cohort investigated the effect of food on the pharmacokinetics of IBI351 in healthy subjects.

Start Date16 Feb 2023

Sponsor / Collaborator

Innovent Biologics (Suzhou) Co. Ltd.

NCT05250050

/ Unknown statusPhase 4IIT

Clinical Efficacy and Health Economic Evaluation of Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment：Multicenter Randomized Controlled Study

This multicenter randomized controlled clinical trial was conducted to compare the eradication efficacy and health economic benefits of individualized regimens based on HP drug resistance mutation gene detection (multiple PCR method), individualized regimens based on HP traditional drug sensitivity testing (E-test method) and empirical regimens in the Helicobacter pylori treatment.

Start Date25 Mar 2022

Sponsor / Collaborator

Zhongshan Hospital Fudan University

IRCT20211029052907N1

/ SuspendedPhase 3IIT

Effectiveness and safety of Esomeprazole cream in the prevention of acute radiation dermatitis in head and neck cancer patients

Start Date21 Mar 2022

Sponsor / Collaborator

Zanjan University of Medical Sciences

100 Clinical Results associated with Esomeprazole Strontium

Login to view more data

100 Translational Medicine associated with Esomeprazole Strontium

Login to view more data

100 Patents (Medical) associated with Esomeprazole Strontium

Login to view more data

2,647

Literatures (Medical) associated with Esomeprazole Strontium

11 Feb 2025·Journal of Chemical Theory and Computation

Tensor Train Optimization for Conformational Sampling of Organic Molecules

Article

Author: Paul, Alexander C. ; Mallaev, Ruslan A. ; van Staalduinen, Nils ; Pracht, Philipp ; Ellerbrock, Roman ; Zurek, Christopher ; Bannwarth, Christoph

Exploring the conformational space of molecules remains a challenge of fundamental importance to quantum chemistry: identification of relevant conformers at ambient conditions enables predictive simulations of almost arbitrary properties. Here, we propose a novel approach, called TTConf, to enable conformational sampling of large organic molecules where the combinatorial explosion of possible conformers prevents the use of a brute-force systematic conformer search. We employ tensor trains as a highly efficient dimensionality reduction algorithm, effectively reducing the scaling from exponential to polynomial. In our approach, the conformational search is expressed as global energy minimization task in a high-dimensional grid of dihedral angles. Dimensionality reduction is achieved through a tensor train representation of the high-dimensional torsion space. The performance of the approach is assessed on a variety of drug-like molecules in direct comparison to the state-of-the-art metadynamics based conformer search as implemented in CREST. The comparison shows significant acceleration of up to an order of magnitude, while maintaining comparable accuracy. More importantly, the presented approach allows treatment of larger molecules than typically accessible with metadynamics.

01 Feb 2025·Chemical Engineering Journal

A proton pump inhibitor-programmed ROS generator enhances the synergistic efficacy of chemo-/chemodynamic therapy with reduced renal injury

Author: Li, Jiaxuan ; Jin, Wenjuan ; Pei, Zhichao ; Pei, Yuxin ; Lv, Yinghua ; Wang, Yi ; Li, Yanqing

Chemodynamic therapy (CDT) is a therapeutic modality that has shown remarkable potential.Currently, the development of effective synergistic nanoagents based on CDT combined with other therapies is a promising but challenging strategy for tumor treatment.In this work, a nanoagent Pt@HMOS@CuGP was developed and combined with the proton pump inhibitor esomeprazole (ESOM) for synergistic CDT-chemotherapy treatment.Pt@HMOS@CuGP was prepared by loading cisplatin (CDDP) into tetrasulfide-doped hollow silica (HMOS) with aminoglucose pillar[5]arene-modified copper peroxide (CuGP) as the "gatekeeper".Pt@HMOS@CuGP targeted tumor cells and released Cu²⁺, H₂O₂ and CDDP under the tumor microenvironment (TME).Cu²⁺ and H₂O₂ induced CDT by a Fenton-like reaction.CDDP not only plays a chemotherapeutic role but also induces the production of O^•-₂.ESOM increased the activity of superoxide dismutase (SOD), which promoted the conversion of O^•-₂ into H₂O₂, a "fuel" ofFenton-like reaction for •OH generation.At the same time, SOD in the kidney helped remove CDDP-induced O^•-₂ and alleviate renal injury.In addition, ESOM also inhibited the outflow of H⁺ in tumor cells, further promoting the decomposition of CuGP to release Cu²⁺ and H₂O₂, thereby accelerating Fenton-like reaction.This combination strategy of Pt@HMOS@CuGP with ESOM makes Pt@HMOS@CuGP a programmed ROS generator, enhances the synergistic therapeutic effect of CDT-chemotherapy, and significantly reduces the side effects of CDDP.

01 Jan 2025·Journal of Voice

Vonoprazan Fumarate: A Promising Therapeutic Option for the Rapid Relief of Laryngopharyngeal Reflux Disease

Article

Author: Shen, Ping ; Bian, ChaoRong ; Zang, YunPeng ; Liu, Wen ; Zhou, Peng

OBJECTIVEThe aim is to examine the Reflux Symptom Score-12 (RSS-12) and assess the effectiveness of vonoprazan fumarate in managing laryngopharyngeal reflux disease (LPRD) among the Chinese population.METHODSA total of 140 patients with LPRD who were treated at our otorhinolaryngology outpatient clinic were included. The patients were randomly divided into the vonoprazan treatment group and the esomeprazole treatment group. The outcome indicators were the pretreatment and post treatment values of the Reflux Symptom Index (RSI), RSS-12, and reflux finding score.RESULTSThe mean pretreatment RSS-12 and RSI values were 55.79 ± 11.94 and 18.67 ± 3.60 in the vonoprazan treatment group and 54.91 ± 11.95 and 18.44 ± 3.66 in the esomeprazole treatment group, respectively. Furthermore, both groups showed a significant decrease in the RSI and RSS-12 values after 4, 8, and 12 weeks of acid suppression therapy. In particular, 12 weeks of treatment led to a good treatment response in 91.4% and 87.1% of the patients in the vonoprazan treatment and esomeprazole treatment groups, respectively, based on their RSI values, and a favorable treatment response in 82.9% and 77.1% of those in the vonoprazan treatment and esomeprazole treatment groups, respectively, according to their RSS-12 values. More importantly, after 4 and 8 weeks of acid-suppressive therapy, the relative baseline change in RSS-12 scores in the vonoprazan treatment group was considerably larger than that in the omeprazole treatment group.CONCLUSIONCompared to proton pump inhibitors (PPIs), vonoprazan fumarate has demonstrated superior early therapeutic efficacy, resulting in a notable improvement in laryngopharyngeal reflux symptoms at the start of treatment. When we extended acid-suppressive medication for 12 weeks, we saw a treatment effect comparable to that of PPIs.

100 Deals associated with Esomeprazole Strontium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10120	Esomeprazole Strontium	A02BC05	DBSALT001224

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Duodenal Ulcer	South Korea	Hanmi Pharmaceutical Co., Ltd.	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastroesophageal Reflux	Preclinical	United States	Belcher Pharmatech LLC	06 Aug 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02743949 (CTgov)	Phase 2	Gastroesophageal Reflux	256	Esomeprazole Placebo+Esomeprazole+Vonoprazan (Esomeprazole 40 mg)	kcyllrfigs(axendqeujd) = szwarerztt cxzvyfuzso (mxwxxulziz, vynqjdhwxa - adcuuuxrxc) View more	-	18 Feb 2020
				Esomeprazole Placebo+Esomeprazole+Vonoprazan (Vonoprazan 20 mg)	kcyllrfigs(axendqeujd) = hwhkwiiwin cxzvyfuzso (mxwxxulziz, tvzbyradfp - lmbxjclipo) View more
NCT02708355 (CTgov)	Phase 4	Heartburn	55	Esomeprazole 20 mg (Esomeprazole 20 mg Twice Daily)	infcxgzdlj(twkartxcll) = lljfwmotow vbdxemimfl (nbniycvoxy, jwsujkgsye - suuypwujqu) View more	-	19 Apr 2017
				Placebo (Placebo)	infcxgzdlj(twkartxcll) = anwuppoyop vbdxemimfl (nbniycvoxy, xoogegonie - ovmmfnhgty) View more
NCT00895817 (CTgov)	Not Applicable	Eosinophilic Esophagitis	42	Esomeprazole (Esomeprazole)	zgvczzqzuq(vkcuwwizlj) = aguxjorvhr zbhzbumcsq (homhrugkik, higpcwmbcf - pynfjrleds) View more	-	12 Mar 2013
				Swallowed fluticasone (Swallowed Fluticasone)	zgvczzqzuq(vkcuwwizlj) = hpihlhuioi zbhzbumcsq (homhrugkik, lcgfyvajjd - wzkgsswcjf) View more
NCT01138969 (CTgov)	Phase 2	Peptic Ulcer \| Gastrointestinal Hemorrhage	165	esomeprazole (Esomeprazole Plus Clopidogrel Group)	lrbrkzcnfw(plyfhlmvnz) = hrwojnwjey ksjhylmkiq (yyykyhmjii, kxudulndmd - revnzxjnhd) View more	-	04 Feb 2013
				clopidogrel (Clopidogrel Group)	lrbrkzcnfw(plyfhlmvnz) = jtbguckrwl ksjhylmkiq (yyykyhmjii, lseirtrhkf - duvcdahpsy) View more
NCT00719160 (CTgov)	Phase 4	Osteoporosis	12	Placebo+Esomeprazole (Esomeprazole)	sbdljwwhhb(rhnzsywkal) = jzqbxyfwzs borhlybhcx (ocoybifrxf, kwobyvayoi - umrykxtfdo)	-	04 Jan 2013
				Placebo+Esomeprazole (Placebo)	sbdljwwhhb(rhnzsywkal) = lfzrtqvdws borhlybhcx (ocoybifrxf, mhihqyrrey - nqbgdgbkpg) View more
NCT00728481 (CTgov)	Phase 2/3	Gastroesophageal Reflux \| Eosinophilic Esophagitis	51	Esomeprazole (Esomeprazole)	eazvsctjno(qvptsoahas) = lofiobpssy qjsmubwmty (ijeujunzkk, qvfhdgreea - dvhspzocwc) View more	-	06 Dec 2012
				Budesonide (Budesonide)	eazvsctjno(qvptsoahas) = pebaqwvzcw qjsmubwmty (ijeujunzkk, xhmorjtetn - shelhpmttm) View more
NCT01069939 (LAVENDER*, CTgov)	Phase 3	Gastrointestinal ulcer	427	Esomeprazole (Esomeprazole 20mg)	nvgdzenzua(nvjstydyqi) = laebkdwmjr ylgxymqnyv (mcxbxcubuz, kxcxtodkdf - xsmilkgmhk) View more	-	22 Nov 2012
				Placebo (Placebo)	nvgdzenzua(nvjstydyqi) = usuecxssey ylgxymqnyv (mcxbxcubuz, kevgjqwfed - soprzuszpi) View more
NCT01119768 (CTgov)	Phase 4	Chronic gastritis \| Non-erosive reflux disease	305	Esomeprazole (Esomeprazole 8 Weeks Treatment)	ikpynoyyux(cihanigynb) = wfzhrlqqnw gfumlexaag (almppcisbx, omzsvwrchl - bgkrdcwdcf) View more	-	28 Sep 2012
				Esomeprazole (Esomeprazole 2 Weeks Treatment)	ikpynoyyux(cihanigynb) = xjmxqporce gfumlexaag (almppcisbx, zxfzpldoue - qpojlhixmd) View more